Richard Francis

Richard Francis leads Teva Pharmaceutical Industries as President and CEO, overseeing the world's largest generic drug manufacturer. Based in Israel, Teva produces over 120 billion doses of generic and branded medications annually, sold in more than 60 countries. The company's generic drugs portfolio includes thousands of molecules across virtually every therapeutic area. Teva has been executing a multi-year turnaround following a period of overleveraged acquisitions (particularly the $40.5 billion Actavis Generics deal in 2016) and opioid litigation costs that pushed the company to the brink. The turnaround strategy centers on: growing biosimilars (including its Humira biosimilar launched in the U.S.), expanding the branded product Ajovy (a CGRP inhibitor for migraine prevention), launching innovative pipeline assets, and aggressively reducing debt. The generic drug industry faces structural headwinds from price erosion and increasing competition, but also benefits from healthcare cost containment pressures that drive substitution from branded to generic medicines. Key stock drivers include generic drug pricing trends, biosimilar launches and market share capture, Ajovy sales growth, pipeline catalysts, opioid litigation resolution and costs, debt reduction progress, and the strategic direction under new leadership to rebalance between generics and innovative medicines.